Hepatocellular carcinoma is the most common form of liver cancer. Credit: Ed Uthman.

Innovent Biologics has commenced dosing in the Phase II/III ORIENT-32 clinical trial of its Tyvyt (sintilimab injection) plus IBI305 combination as first-line therapy for advanced hepatocellular carcinoma (HCC), a common type of liver cancer.

Tyvyt is a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

IBI305 is a recombinant humanised monoclonal antibody and a biosimilar candidate of bevacizumab that targets vascular endothelial growth factor (VEGF).

The randomised, open-label, multi-centre ORIENT-32 trial is designed to assess the safety and efficacy of the combination therapy, compared to sorafenib, in 566 participants.

The primary endpoint of the trial is overall survival, while the primary outcome measures also include objective response rate.

“The development of new agents for the treatment of advanced HCC has been stagnant, so there is a huge unmet clinical need.”

Second outcome measures are disease control rate, duration of response, time to progression, progression-free survival and time to response.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Innovent Biologics founder, CEO and chairman Michael Yu said: “The development of new agents for the treatment of advanced HCC has been stagnant, so there is a huge unmet clinical need.

“Based on the encouraging data we have observed in our Phase Ib study, we have decided to conduct the ORIENT-32 trial, a Phase II/III study in first-line advanced HCC.”

Innovent is developing Tyvyt in China in alliance with Eli Lilly. Sintilimab injection is currently undergoing 20 clinical studies for a variety of solid tumours.

The therapeutic received marketing approval from the National Medical Products Administration (NMPA) in China for treating relapsed or refractory classical Hodgkin’s lymphoma (r/r cHL).

Innovent announced acceptance of IBI305’s new drug application (NDA) last month.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact